InMed's Alzheimer's Drug Candidate INM-901 Shows Favorable Bioavailability in Large Animal Studies
核心洞察
InMed Pharmaceuticals successfully completed pharmacokinetic studies of INM-901 in large animal models, demonstrating robust bioavailability and therapeutic levels of systemic exposure over a seven-day dosing period.
Neurological assessments revealed no adverse neural or behavioral effects, reinforcing the compound's favorable safety profile and supporting advancement toward first-in-human clinical trials.
The company is preparing for a pre-IND meeting with the FDA and advancing chemistry, manufacturing, and controls development to scale the INM-901 manufacturing process.
InMed Pharmaceuticals Inc. (NASDAQ: INM) announced the successful completion of pharmacokinetic studies in large animal models for its Alzheimer's disease (搜索) candidate INM-901, marking a significant milestone in the compound's preclinical development. The studies demonstrated favorable bioavailability and safety profiles that support the drug's advancement toward human clinical trials.
Positive Pharmacokinetic Results
The seven-day dosing study revealed robust bioavailability in in vivo models, with INM-901 achieving what the company anticipates to be therapeutic levels of systemic exposure. This represents the first preclinical study in which the oral formulation of INM-901 was administered in large animals, providing crucial data for the design of a human Phase 1 clinical trial program.
The results support INM-901's potential utility in neurodegenerative disorders (搜索) such as Alzheimer's disease (搜索), demonstrating that the oral formulation can achieve meaningful systemic exposure levels necessary for therapeutic efficacy.
Safety Profile Reinforced
Neurological assessments conducted during the study evaluated general attitude, behavior, and motor function in the animal models. The evaluations revealed no adverse neural or behavioral effects, reinforcing the compound's favorable safety profile and supporting its continued advancement toward first-in-human clinical trials.
Dr. Eric Hsu, Senior Vice President, Preclinical Research and Development at InMed, commented, "The successful completion of our first large animal PK study is very encouraging for the INM-901 program. The data supports the clinical applicability of our INM-901 oral formulation and provides important insights as we plan and design our IND-enabling studies and Phase 1 clinical trials. Furthermore, the neurological assessments strengthen our confidence in the compound's overall safety profile."
Manufacturing and Regulatory Preparations
In parallel with the pharmacokinetic studies, InMed has completed additional chemistry, manufacturing, and controls (CMC) development to scale the INM-901 manufacturing process. This work prepares the company for Investigational New Drug (IND)-enabling studies and regulatory interaction with the Food and Drug Administration (搜索) (FDA).
The company has outlined its next development steps, which include advancing CMC activities for scale-up and supply, conducting dose ranging studies in two species, preparing for a pre-IND meeting with the FDA, and initiating GLP-enabling studies to support an IND submission.
CB1/CB2 Receptor Targeting Approach
InMed Pharmaceuticals focuses on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors (搜索). The company's pipeline consists of three separate programs addressing Alzheimer's, ocular, and dermatological indications, with INM-901 representing the lead candidate for neurodegenerative disorders (搜索).